Swiss pharma giant Novartis’ (NOVN: VX) generics and biosimilars subsidiary Sandoz today announced that the US Food and Drug Administration (FDA) approved its biosimilar Ziextenzo (pegfilgrastim-bmez).
The FDA decision follows a previous rejection of the biosimilar application and a re-submission in April this year.
Sandoz biosimilar pegfilgrastim, which references Amgen’s (Nasdaq: AMGN) Neulasta, has been approved and marketed in Europe as Ziextenzo (pegfilgrastim) since 2018. Global sales of Neulasta were down 32% at $711 million for the third-quarter of this year, as a results of lower net selling price and biosimilar competition. Sandoz now intends to launch Ziextenzo in the USA as soon as possible this year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze